WHEN A BIOTECH SAYS NO TO $30B PAY ATTENTION — BUYOUT TARGET
By Nigam Arora Buyout Talks Revolution Medicines (RVMD) was in talks to be acquired by Merck (MRK). The deal was valued around $30B. Apparently, Revolution Medicines wants a higher offer than Merck is willing to extend at this time. In The Arora Report analysis, this indicates Revolution Medicines has enough confidence
January 27, 2026